SQZ Biotechnologies EBITDA Margin 2020-2021 | SQZ

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current EBITDA margin for SQZ Biotechnologies as of September 30, 2021 is .
SQZ Biotechnologies EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-09-30 $0.02B $-0.06B -376.47%
2021-06-30 $0.02B $-0.05B -300.00%
2021-03-31 $0.02B $-0.05B -236.84%
2020-12-31 $0.02B $-0.04B -200.00%
2020-06-30 $0.02B $-0.02B -143.75%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.178B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88